



Universiteit  
Leiden  
The Netherlands

## The role of ATF2 in insulin action

Baan, B.

### Citation

Baan, B. (2009, June 23). *The role of ATF2 in insulin action*. Retrieved from <https://hdl.handle.net/1887/13861>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/13861>

**Note:** To cite this publication please use the final published version (if applicable).

# 3

**The nuclear appearance of ERK and p38 determines the sequential induction of ATF2-Thr71 and ATF2-Thr69-phosphorylation by serum in JNK-deficient cells**

*Manuscript conditionally accepted for publication*

## Chapter 3

### Chapter 3

#### **The nuclear appearance of ERK and p38 determines the sequential induction of ATF2-Thr71 and ATF2-Thr69-phosphorylation by serum in JNK-deficient cells**

Bart Baan, Gerard C.M. van der Zon, J. Antonie Maassen and D. Margriet Ouwens

From the Department of Molecular Cell Biology, Section Signal Transduction and Ageing, Leiden University Medical Centre, Leiden, the Netherlands

**Growth factors activate ATF2 via sequential phosphorylation of Thr69 and Thr71, where the ATF2-Thr71-phosphorylation precedes the induction of ATF2-Thr69+71-phosphorylation. Here, we studied the mechanisms contributing to serum-induced two-step ATF2-phosphorylation in JNK1,2-deficient embryonic fibroblasts. Using anion exchange chromatography, ERK1/2 and p38 were identified as ATF2-kinases in vitro. Inhibitor studies as well as nuclear localization experiments show that the sequential nuclear appearance of ERK1/2 and p38 determines the induction of ATF-Thr71 and ATF2-Thr69+71-phosphorylation in response to serum.**

ATF2 is a ubiquitously expressed member of the cAMP-responsive element (CRE)-binding protein family of basic region-leucine zipper (bZIP) transcription factors also including CREB (1) and ATF3, ATF4, ATF6 and B-ATF (2;3). ATF2 can form homo- and heterodimers with other ATF-family members (3), but also with the activating protein-1 (AP-1) family member cJun (4). The various dimer compositions confer an enormous repertoire of target genes on ATF2, which include cell cycle regulators, proteins involved in invasion or adhesion, growth factors and pro-inflammatory cytokines, DNA repair genes, transcriptional factors and molecules associated with metabolic control (5;6).

In the absence of a stimulus, ATF2 is held in an inactive conformation (7). Phosphorylation of residues within the activation domain leads to ATF2 transcriptional activation (8-10). In particular, phosphorylation of two threonine (Thr) residues, Thr69 and Thr71, is required and sufficient for transcriptional activation of ATF2 (11;12).

Inducers of cellular stress, like pro-inflammatory cytokines, oncogenes, viruses, heat shock, osmotic stress and DNA-damaging agents as well as growth factors, increase the transactivation capacity of ATF2 through phosphorylation of the Thr69 and Thr71 residues. The activation pattern induced by mitogens, however, differs from that mediated by inducers of cellular stress. Cellular stresses induce a prolonged phosphorylation of ATF2, whereas the activation induced by growth factors is much more transient and, importantly, is elicited via a two-step mechanism (13). Within minutes after the addition of growth factors, phosphorylation of ATF2-Thr71 is induced, whereas subsequent phosphorylation of ATF2-Thr69 occurs several minutes later. Notably, this mechanism involves cooperation of distinct Ras-effector pathways. The Ras-Raf-MEK-ERK1/2 pathway directs the phosphorylation of ATF2-Thr71, whereas the Ras-Ral pathway is required for subsequent ATF2-Thr69 phosphorylation.

Here, we studied the mechanisms contributing to serum-induced two-step ATF2-phosphorylation in JNK1,2-deficient embryonic fibroblasts. Therefore, ATF2 kinases were purified from serum-treated cells by anion exchange chromatography. Using pharmacological inhibitors and nuclear localization experiments, we further detailed the


## Chapter 3

role of the purified kinases in the serum-mediated induction of ATF2-Thr71 and ATF2-Thr69+71-phosphorylation, respectively.

### Results

*The main ATF2 N-terminal kinase activities co-purify with ERK1/2 and p38 in serum-treated JNK1,2<sup>-/-</sup> cells.* To identify ATF2-kinases in JNK1,2<sup>-/-</sup> cells, cell lysates prepared after 10 min of serum stimulation were fractionated by anion-exchange chromatography on monoQ columns. Analysis of the obtained fractions showed that the bulk of ATF2-directed kinase activity co-purified with fractions containing ERK1/2. A smaller peak of ATF2-directed kinase activity was recovered in a fraction co-purifying with p38 (Figure 1A, solid line).

Incubation of the cells with U0126, an inhibitor of the upstream activator of ERK1/2: MEK1/2 (14), strongly reduced the serum-induced ATF2 kinase activity in the fractions co-purifying with ERK1/2 (Figure 1A, dashed line). Furthermore, addition of the p38 inhibitor SB203580 (15) to the *in vitro* kinase assay completely blocked ATF2-kinase activity in the fraction co-purifying with p38 (Figure 1B). Similar results were obtained for JNK1,2<sup>-/-</sup> cells treated with epidermal growth factor (EGF) (data not shown). Thus, the major ATF2-directed kinase activities in growth factor stimulated JNK1,2<sup>-/-</sup> cells are represented by ERK1/2 and p38.




**Figure 1. Identification of ERK1/2 and p38 as the major ATF2 kinases activities in JNK<sup>-/-</sup> cells.** (A) JNK<sup>-/-</sup> cells, pretreated with vehicle (solid line) or U0126 (dashed line) for 15 minutes, were FCS stimulated for 10 minutes before lysis. MonoQ anion exchange-fractionation was performed on these lysates and the obtained fractions were used in an ATF2-directed *in vitro* kinase assay using GST-ATF2 as substrate. ATF2-Thr71 specific phosphorylation of GST-ATF2 was determined by Western blotting using the ATF2-Thr71 phospho-specific antibody. Relative ATF2-Thr71 reactivity was plotted against MonoQ fraction number. The presence of phospho-ERK1/2 and p38 MAPK in the different fractions was determined by western blotting. (B) The p38-containing MonoQ fraction (#17) was used in an *in vitro* kinase assay in the presence of vehicle or SB203850 with GST-ATF2 as the substrate. ATF2-Thr71 specific phosphorylation of GST-ATF2 was determined by Western blotting using a ATF2-Thr71 phospho-specific antibody.

## ATF2-phosphorylation in JNK<sup>-/-</sup> cells

*Inhibition of ERK1/2 and p38 differentially abrogates ATF2-Thr71 and ATF2-Thr69+71 phosphorylation in serum-stimulated JNK1,2<sup>-/-</sup> cells.* As both ERK1/2 and p38 were identified as ATF2-directed kinases from JNK1,2<sup>-/-</sup> cells, we next analyzed the effects of U0126 and SB203580 on serum-induced ATF2-Thr71 and ATF2-Thr69+71 phosphorylation. Western blot analysis of lysates of JNK1,2<sup>-/-</sup> cells, showed that ATF2-Thr71 phosphorylation was induced after 2-4 min, whereas the onset of ATF2-Thr69+71 was detected at 4-6 min after serum addition (Figure 2A).


The presence of SB203580 lowered the absolute levels of Thr71-phosphorylated ATF2 both in the basal state as well as following incubation with serum (Figure 2B/C). However, the fold-induction (as compared to t=0 minutes) of ATF2 Thr71-phosphorylation by serum was slightly enhanced in the presence of SB203580 (Figure 2B/C). The complete inhibition of the serum-induced phosphorylation of MAPKAPK-2 (16), another downstream target of p38, confirmed effectiveness of SB203580 (Figure 2D). In contrast to SB203580, the presence of U0126 completely abrogated the induction of ATF2-Thr71 phosphorylation by serum (Figure 2B). These results suggest that, in these cells, ERK1/2 rather than p38 is responsible for the phosphorylation of ATF2 on Thr71 observed at 2-4 minutes after serum stimulation. In line with previous reports showing that ERK1/2 is not capable of phosphorylating ATF2 on Thr69 (13;17), the presence of SB203580, but not U0126, completely prevented serum-induced ATF2-Thr69+71-phosphorylation in JNK1,2<sup>-/-</sup> cells (Figure 2B).



**Figure 2. Inhibition of ERK1/2 and p38 differentially abrogates ATF2-Thr71 and ATF2-Thr69+71 phosphorylation in serum-stimulated JNK1,2<sup>-/-</sup> cells.** (A) Serum-starved JNK<sup>-/-</sup> cells were treated with 20% fetal calf serum (FCS). Total cell lysates were prepared at indicated time-points and analyzed by Western blotting using phospho-specific ATF2-Thr71 and ATF2-Thr69+71 antibodies. (B) Serum-starved JNK<sup>-/-</sup> cells were pre-incubated for 30 minutes with vehicle or inhibitors U0126 or SB203580 before serum-stimulation (FCS; 20%) for the times indicated. ATF2-Thr71- and Thr69+71-phosphorylation levels were determined by immunoblotting with specific antibodies. (C) The relative ATF2-Thr71 phosphorylation of the vehicle and SB203580-treated lysates were quantified and plotted against the time of stimulation. (D) Serum-starved JNK<sup>-/-</sup> cells were treated with carrier or SB, FCS-stimulated for 10 minutes and lysed as described above. MAPKAPK-2 phosphorylation was determined by immunoblotting.

### Chapter 3

The onset of ATF2-Thr71 and ATF2-Thr69+71-phosphorylation associates with nuclear translocation of ERK1/2 and p38. Immunofluorescence experiments showed that phosphorylated ATF2 is localized in the nucleus and confirmed that the p38 inhibitor SB203580 abolished serum-induced phosphorylation of ATF2-Thr69+71, but not of ATF2-Thr71 (Figure 3).




**Figure 3. Serum-induced ATF2-Thr69+71, but not Thr71-phosphorylation is SB203580-sensitive in JNK<sup>-/-</sup> cells.** Serum-starved JNK<sup>-/-</sup> cells were treated with SB203580 (SB) for 30 minutes prior to stimulation with 20% serum (FCS) for 8 minutes. Cells were fixed and stained with antibodies for (A) Thr71- or (B) Thr69+71-phosphorylated ATF2 followed by FITC-conjugated secondary antibodies (green). DNA was stained with DAPI (blue). Full-colour illustration can be found at page 122.

## ATF2-phosphorylation in JNK<sup>-/-</sup> cells

Serum stimulation of JNK1,2<sup>-/-</sup> cells induced the phosphorylation of both ERK1/2 and p38 within 2 minutes (Figure 4A). As the MAPkinases involved in ATF2-phosphorylation are simultaneously activated, their sequential role in ATF2-phosphorylation cannot simply be explained by sequential activation. Therefore, we determined if differences in nuclear appearance of ERK1/2 and p38 might determine the differential onset of ATF2-Thr71 and ATF2-Thr69+71 phosphorylation.

Using cell fractionation and immunofluorescence procedures, we found that within 2 minutes, serum induced the nuclear translocation of phosphorylated ERK1/2 (Figure 4B/5A) and that this was paralleled by the induction of ATF2-Thr71 phosphorylation (Figure 4B). Nuclear translocation of phosphorylated p38 was observed 4 minutes after serum addition and was paralleled by ATF2-Thr69+71 phosphorylation (Figure 4B/5A).

Purity of the cell fractions was checked by Western Blotting, using EF-1 $\beta$  and Lamin A antibodies as cytosolic and nuclear markers, respectively (Figure 4C).




**Figure 4.** The onset of ATF2-Thr71 and ATF2-Thr69+71-phosphorylation coincides with the appearance of ERK1/2 and p38 in nuclear fractions (A) Lysates from serum-starved JNK<sup>-/-</sup> cells prepared at the indicated time points after FCS stimulation were examined for phosphorylation of ERK1/2 and p38 and ATF2-Thr71 and Thr69+71 by immunoblotting with phospho-specific antibodies as described. (B) Serum-starved JNK<sup>-/-</sup> cells were serum-stimulated as described, at the times indicated cellular fractions were prepared and the nuclear fractions examined for phosphorylation of ERK1/2 and p38 and ATF2-Thr71 and Thr69+71 by immunoblotting with phospho-specific antibodies as described. (C) Serum-starved JNK<sup>-/-</sup> cells were serum-stimulated as described, at the times indicated cellular fractions were prepared and the purity of both cytosolic (CF) and nuclear (NF) fractions was examined by immunoblotting with Elongation Factor (EF)-1 beta and Lamin A-specific antibodies.



### Chapter 3

Finally, the presence of SB203580 abrogated nuclear phospho-p38 immunoreactivity found in response to serum (Figure 5B) and severely reduced the serum-induced phospho-ATF2-Thr69+71 and phospho-p38 signals in nuclear extracts (Figure 5C).



**Figure 5.** The onset of ATF2-Thr71 and ATF2-Thr69+71-phosphorylation associates with nuclear translocation of ERK1/2 and p38. (A) Serum-starved JNK<sup>-/-</sup> cells were stimulated with 20% serum (FCS) and fixed at the times indicated. The fixed cells were stained with antibodies for phospho-ERK1/2 (ERK1/2-PP) or phospho-p38 (p38-PP) followed by FITC-conjugated secondary antibodies (green). DNA was stained with DAPI (blue). (B) Serum-starved JNK<sup>-/-</sup> cells pre-treated with vehicle or SB203850 for 30 minutes prior to 8 minute FCS-stimulation were fixed and stained for phospho-p38 (p38-PP) as described above. (C) Serum-starved JNK<sup>-/-</sup> cells, pre-treated with vehicle or SB203850 were serum-stimulated for 8 minutes, after which cellular fractions were prepared and the nuclear fractions examined for p38- and ATF2-Thr69+71 phosphorylation by immunoblotting with phospho-specific antibodies as described. Full-colour illustration can be found at page 123.

### Discussion

The present study identifies the MAP kinases ERK1/2 and p38 as the major growth factor-induced ATF2-directed kinases in JNK<sup>-/-</sup> cells and elucidates their role in two-step ATF2-phosphorylation mechanism in response to growth factors.

Using MonoQ anion exchange chromatography we found that, in JNK<sup>-/-</sup> cells, the major serum-induced ATF2-directed kinase activities co-purified with the ERK1/2 and p38 fractions (Figure 1A). MonoQ separation of EGF- or insulin-stimulated JNK-deficient cell lysates resulted in similar ATF2-kinase profiles (data not shown), suggesting that these kinases are involved in general mitogenic signaling towards ATF2.

The role of ERK1/2 and p38 in serum-stimulated ATF2 phosphorylation in JNK-deficient fibroblasts was further established by inhibitor studies: treatment of these cells with U0126 abolished the serum-induced ATF2-kinase activity in the ERK1/2-containing fraction and reduced the early ATF2 phosphorylation on Thr71 found in cell lysates (Figure 1 and 2) This suggests that ERK is the kinase responsible for the first phosphorylation of ATF2 on Thr71 in response to serum.

As ERK1/2 is incapable of phosphorylating ATF2 on Thr69 (13;17), cooperation with another kinase seems necessary for efficient ATF2-Thr69+71 phosphorylation. Our study identified p38 as the other ATF2-directed kinase in serum-treated JNK<sup>-/-</sup> cells. p38 is known to be capable of phosphorylating ATF2 on both Thr69 and 71 residues (13;17;18). In response to inducers of cellular stress the onset of ATF2-Thr69+71 coincides with the onset of ATF2-Thr71-phosphorylation and this process seems completely p38-dependent in JNK-deficient cells (13;17). This raises the question whether activation of p38 alone may be sufficient for the induction of ATF2-phosphorylation in response to serum. Our data suggest that ERK1/2 activation is biologically relevant for serum-induced two-step ATF2-phosphorylation. In contrast to ERK1/2, the activity of p38 is low in serum-stimulated fibroblasts and, therefore, insufficient to phosphorylate ATF2 Thr71 and/or Thr69 efficiently by itself. However, these low levels of active p38 are essential and appear to be sufficient to phosphorylate Thr69 when ATF2 is already mono-phosphorylated on Thr71 by ERK1/2. Furthermore, recombinant p38 was reported to phosphorylate GST-ATF2 via a double collision mechanism *in vitro* (19). After the first (random) phosphorylation event of ATF2 on Thr69 or Thr71, p38 dissociates from the mono-phosphorylated ATF2 substrate. It then re-associates with ATF2 for phosphorylation of the second threonine. Importantly, the efficiency of the second phosphorylation step is differentially affected by the two mono-phosphorylated forms of ATF2: whereas Thr71-phosphorylated ATF2 was readily phosphorylated on Thr69, ATF2 mono-phosphorylated on Thr69 was found to be an inefficient substrate for p38-mediated Thr71- phosphorylation. Thus, efficient phosphorylation of ATF2 by recombinant active p38 only occurs in the order Thr71 → Thr69+71. In our JNK-deficient system, phosphorylation of ATF2-Thr71 by ERK1/2 might prime ATF2 for subsequent efficient ATF2-Thr69-phosphorylation by p38. Accordingly, inhibiting p38 activity reduced the ATF2-directed activity present in p38-containing MonoQ fraction and abolished the serum-induced ATF2-Thr69 phosphorylation found in JNK<sup>-/-</sup> cell lysates (Figure 1, 2 and 3). These findings suggest that in these cells, ERK1/2 and p38 cooperate to efficiently phosphorylate ATF2 on Thr69 and Thr71.

Finally, localization studies using cell fractioning and immunofluorescence experiments showed that although ERK1/2 and p38 are activated simultaneously in response to serum in JNK<sup>-/-</sup> cells, the nuclear appearance of these kinases is different, with nuclear presence of ERK1/2 preceding p38. Notably, the nuclear appearance of ERK1/2 correlated with the ATF2-Thr71 phosphorylation, while nuclear translocation of p38

## Chapter 3

paralleled the detection of phospho-Thr69+71 ATF2. In addition, treatment of JNK<sup>-/-</sup> cells with SB203580, which abolished ATF2-Thr69+71 phosphorylation, also prevented nuclear appearance of phosphorylated p38. These results suggest that despite simultaneous activation of ERK1/2 and p38 by serum, their differential nuclear appearances can explain the differential kinetics of ATF2 phosphorylation.

The data presented in this study suggest that the serum-induced two-step mechanism of ATF2-phosphorylation in JNK-deficient cells is dependent on cooperation of ERK1/2 with p38. We propose that sequential nuclear appearance of these kinases is a determining factor driving this mechanism.

### Materials and Methods

*Cell culture and cell stimulation.* JNK8 cells (JNK1 and 2 knockout embryonic fibroblasts) were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 9% fetal bovine serum (FBS) and antibiotics. Before cell-stimulations, the cells were serum-starved (DMEM w/ 0.5% FBS) for 16h. When inhibitors were used, cells were pre-treated for 30 minutes with 2.5  $\mu$ M SB203580 (Promega) or for 15 minutes with 10  $\mu$ M U0126 (Promega), before addition of serum (FCS) to 20%.

*Western blot analysis and antibodies.* Whole cell lysates were prepared from 9 cm dishes that were rinsed twice with ice-cold phosphate-buffered saline (PBS) and lysed in 750  $\mu$ l Laemmli sample buffer. Proteins were separated on polyacrylamide slab gels and transferred to Immobilon (Millipore). Blots were stained with Ponceau S before blocking to verify equal loading and appropriate protein transfer. Filters were incubated with antibodies as described previously (13). The antibodies used were: Lamin A and phospho-specific ATF2-Thr69+71, ATF2-Thr71, p38-Thr180/Tyr182, ERK1/2-Thr202/Tyr204 and MAPKAPK2-P (all polyclonal, Cell Signaling); p38 (N-20), ATF2 (C-19) and ERK1/21 (K-23) (Santa Cruz) and secondary antibodies: goat anti-rabbit and goat anti-mouse IgG-HRP conjugate (Promega). The Elongation Factor (EF)-1 $\beta$  antibody was described previously (20). The specificity of the phospho-specific ATF2 antibodies (P71 and P69+71) has been verified previously (13;17).

*MonoQ/anion-exchange chromatography.* Anion-exchange chromatography was performed essentially as described previously (13). Briefly, stimulated cells were scraped in MonoQ lysis buffer [20 mM Tris (pH 7.0), 0.27 M sucrose, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 10 mM sodium  $\beta$ -glycerolphosphate, 50 mM NaF, 5 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 0.1% (v/v)  $\beta$ -mercaptoethanol and Complete protease inhibitors (Roche Biochemicals)]. Lysates of six 9-cm dishes (~8000 mg protein) were diluted twofold with MonoQ buffer [50 mM Tris.Cl (pH 7.5), 1 mM EDTA, 1 mM EGTA, 5% (v/v) glycerol, 0.03% (w/v) Brij-35, 1 mM benzamidine, 0.3 mM sodium orthovanadate and 0.1% (v/v)  $\beta$ -mercaptoethanol] and applied to a MonoQ HR 5/5 column (Amersham Pharmacia Biotech) equilibrated in MonoQ buffer. After washing, the column was developed with a linear salt gradient to 700 mM NaCl in MonoQ buffer and fractions of 1 ml were collected. Aliquots of 10  $\mu$ l from each fraction were used in *in vitro* ATF2 kinase assays.

*Preparation of cellular fractions.* For cell fractionation experiments, lysates were prepared from 9 cm dishes that were rinsed twice with ice-cold phosphate buffered saline (PBS) and scraped in 1 ml of cold RIPA buffer [30 mM Tris-HCl pH 7.5, 1mM EDTA, 150 mM NaCl, 0.5% Triton X-100, 0.5% Na-DOC, 1 mM sodium orthovanadate, 10 mM sodium fluoride and Complete protease inhibitors (Roche)]. Nuclei were pelleted by centrifugation

## ATF2-phosphorylation in JNK<sup>-/-</sup> cells

(10 min, 14000 rpm, 4°C). Supernatants were collected and stored as cytosolic fractions. Nuclear pellets were washed twice with RIPA and Laemmli buffer was added. Before western blotting nuclear samples were sonicated and boiled. Purity of the cell fractions was checked by Western Blotting, using EF-1 $\beta$  and Lamin A antibodies as cytosolic and nuclear markers, respectively (Figure 4C).

*ATF2 kinase assays.* For *in vitro* ATF2 kinase assays, equal volumes of MonoQ-fractions and equal amounts of protein from cytosolic or nuclear extracts were incubated at 30°C with 2  $\mu$ g of purified GST-ATF2-N substrate (12) and 50  $\mu$ M ATP in a total volume of 60  $\mu$ l of kinase buffer [25 mM HEPES, pH 7.4, 25 mM MgCl<sub>2</sub>, 25 mM  $\beta$ -glycerolphosphate, 5 mM  $\beta$ -mercaptoethanol and 100  $\mu$ M sodium orthovanadate]. When indicated, kinase assays were performed in the presence of vehicle (DMSO) or inhibitor SB203580 (2.5  $\mu$ M). Reactions were terminated by the addition of 20  $\mu$ l of 4x Laemmli buffer and subsequently analyzed by SDS-PAGE/immunoblotting with phospho-specific ATF2-Thr71 antibodies. Blots were quantitated using Scion Image software.

*Immunofluorescence.* Cells were grown on coverslips. After stimulation, cells were washed twice with ice-cold PBS and subsequently fixed in 3.7% formaldehyde in PBS for 15 minutes at room temperature. Coverslips were washed with Tris buffered saline [TBS; 25 mM Tris, 100 mM NaCl, 5 mM KCl, 0.7 mM CaCl<sub>2</sub>·2H<sub>2</sub>O, 0.5 MgCl<sub>2</sub>·6H<sub>2</sub>O] and permeabilised for 5 minutes with 0.1% Triton X-100 in TBS, subsequently washed with 0.2% BSA/TBS, blocked for 30 minutes in 2% BSA/TBS at room temperature and then incubated overnight at 4°C with primary antibodies diluted 1:250 in 0.2% BSA/TBS. After 0.2% BSA/TBS washes, coverslips were incubated with appropriate secondary antibodies diluted 1:100 in 0.2% BSA/TBS for 2 hrs at room temperature. Thereafter coverslips were washed sequentially with 0.2% BSA/TBS and TBS, mounted in DAPI-containing Vectashield solution (Vector Laboratories) and fixed with nail polish. Fluorescence was detected using a Leica DM-RXA microscope. Pictures were acquired as color images (MERGE) and prepared using Photopaint and Coreldraw software.

## References

1. Mayr, B. and Montminy, M. (2001) *Nat. Rev. Mol. Cell Biol.* **2**, 599-609
2. Hai, T. and Hartman, M. G. (2001) *Gene* **273**, 1-11
3. Hai, T. W., Liu, F., Coukos, W. J., and Green, M. R. (1989) *Genes Dev.* **3**, 2083-2090
4. Hai, T. and Curran, T. (1991) *Proc. Natl. Acad. Sci. U. S. A* **88**, 3720-3724
5. Bhoumik, A., Lopez-Bergami, P., and Ronai, Z. (2007) *Pigment Cell Res.* **20**, 498-506
6. Vlahopoulos, S. A., Logotheti, S., Mikas, D., Giarika, A., Gorgoulis, V., and Zoumpourlis, V. (2008) *Bioessays* **30**, 314-327
7. Li, X. Y. and Green, M. R. (1996) *Genes Dev.* **10**, 517-527
8. Sakurai, A., Maekawa, T., Sudo, T., Ishii, S., and Kishimoto, A. (1991) *Biochem. Biophys. Res. Commun.* **181**, 629-635
9. Sevilla, A., Santos, C. R., Vega, F. M., and Lazo, P. A. (2004) *J. Biol. Chem.* **279**, 27458-27465
10. Ban, N., Yamada, Y., Someya, Y., Ihara, Y., Adachi, T., Kubota, A., Watanabe, R., Kuroe, A., Inada, A., Miyawaki, K., Sunaga, Y., Shen, Z. P., Iwakura, T., Tsukiyama, K., Toyokuni, S., Tsuda, K., and Seino, Y. (2000) *Diabetes* **49**, 1142-1148
11. Livingstone, C., Patel, G., and Jones, N. (1995) *EMBO J.* **14**, 1785-1797
12. van Dam, H., Wilhelm, D., Herr, I., Steffen, A., Herrlich, P., and Angel, P. (1995) *EMBO J.* **14**, 1798-1811

### Chapter 3

13. Ouwens, D. M., De Ruiter, N. D., Van Der Zon, G. C., Carter, A. P., Schouten, J., Van Der Burgt, C., Kooistra, K., Bos, J. L., Maassen, J. A., and van Dam, H. (2002) *EMBO J.* **21**, 3782-3793
14. Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., Copeland, R. A., Magolda, R. L., Scherle, P. A., and Trzaskos, J. M. (1998) *J. Biol. Chem.* **273**, 18623-18632
15. Cuenda, A., Rouse, J., Doza, Y. N., Meier, R., Cohen, P., Gallagher, T. F., Young, P. R., and Lee, J. C. (1995) *FEBS Lett.* **364**, 229-233
16. Rouse, J., Cohen, P., Trigon, S., Morange, M., Alonso-Llamazares, A., Zamanillo, D., Hunt, T., and Nebreda, A. R. (1994) *Cell* **78**, 1027-1037
17. Morton, S., Davis, R. J., and Cohen, P. (2004) *FEBS Lett.* **572**, 177-183
18. Raingeaud, J., Gupta, S., Rogers, J. S., Dickens, M., Han, J., Ulevitch, R. J., and Davis, R. J. (1995) *J. Biol. Chem.* **270**, 7420-7426
19. Waas, W. F., Lo, H. H., and Dalby, K. N. (2001) *J. Biol. Chem.* **276**, 5676-5684
20. Sanders, J., Brandsma, M., Janssen, G. M., Dijk, J., and Moller, W. (1996) *J. Cell Sci.* **109**, 1113-1117